Related Experiment Video

Updated: May 15, 2026

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

Arachidonic acid and lipoxin A4 as possible endogenous anti-diabetic molecules

Undurti N Das1

  • 1UND Life Sciences, 13800 Fairhill Road 321, Shaker Heights, OH 44120, USA. Undurti@hotmail.com

Prostaglandins, Leukotrienes, and Essential Fatty Acids
|January 9, 2013
PubMed

Insights

Arachidonic acid (AA) and its derivatives, like lipoxin A4 (LXA4), may prevent diabetes by reducing inflammation and oxidative stress. Supplementation with AA and related compounds could aid in managing and preventing type 1 and type 2 diabetes mellitus.

Area of Science:

  • Biochemistry
  • Immunology
  • Endocrinology

Background:

  • Type 1 and type 2 diabetes mellitus involve increased pro-inflammatory cytokines and reactive oxygen species (ROS), leading to beta-cell apoptosis and insulin resistance.
  • The precise mechanisms driving elevated interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and ROS in diabetes remain unclear.
  • Reduced plasma levels of arachidonic acid (AA) and lipoxin A4 (LXA4) are observed in experimental diabetes and type 2 diabetes mellitus patients.

Purpose of the Study:

  • To investigate the role of arachidonic acid (AA) and its metabolites in the pathogenesis and potential treatment of diabetes mellitus.
  • To explore the anti-inflammatory and antioxidant properties of AA, lipoxins, resolvins, and protectins in the context of diabetes.

Main Methods:

  • Observational studies on plasma concentrations of AA and LXA4 in diabetic models and patients.
  • Experimental administration of AA, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) in chemical-induced diabetes models.
  • Assessment of the effects of AA, LXA4, resolvins, and protectins on cytokine production and ROS generation.

Main Results:

  • Administration of AA, EPA, and DHA protected against chemically induced diabetes, correlating with increased LXA4 and resolvin formation.
  • Protectin D1 effectively ameliorated peripheral insulin resistance.
  • AA, LXA4, resolvins, and protectins demonstrated inhibition of IL-6 and TNF-α production and suppression of ROS generation.

Conclusions:

  • Arachidonic acid (AA) and its derivatives (lipoxins, resolvins, protectins) may act as endogenous anti-diabetic agents.
  • These compounds show potential for preventing and managing both type 1 and type 2 diabetes mellitus due to their anti-inflammatory and ROS-suppressing effects.

More Related Videos

Measurement of Basal and Forskolin-stimulated Lipolysis in Inguinal Adipose Fat Pads07:59

Measurement of Basal and Forskolin-stimulated Lipolysis in Inguinal Adipose Fat Pads

Published on: July 21, 2017

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Lipid-derived Compounds in the Human Body01:31

Lipid-derived Compounds in the Human Body

Fats and lipids are crucial components in the human body. Some lipid-derived compounds, such as fat-soluble vitamins, eicosanoids, lipoproteins, and glycolipids, also play unique roles to support various  biological processes .
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin, delayed...
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...